Interim Prediction of Two-year All-cause Mortality in Patients with de novo Multivessel Coronary Artery Disease Undergoing Intended Multivessel PCI
M Renkens
In 563 patients, the median predicted 2-year all-cause mortality was 1.9%
Older age, impaired LVEF, and an increased anatomical SYNTAX-I score were the main contributors to high mortality
Accurate prediction helps in
Mortality risk prediction
3VD patients to make informed choices
Utilize intravascular imaging techniques for the disease
Percutaneous Coronary Intervention and Medical Therapy versus Medical Therapy Alone in Chronic Coronary Syndrome: A Hierarchical Win-ratio Analysis from SCAAR
S Von Koc
Revascularization with PCI did not result in better outcomes when compared to medical therapy alone
For patients with CCS, medical therapy may be just as effective as PCI in improving outcomes
Predicting the Death Caused by Cardiovascular and/or Cerebrovascular Disease within 7 Years Follow-up Using Machine Learning Models
K Tsarapatsani
LightGBM was the most accurate model, achieving 87.56 %
Machine learning models achieved accurate prediction of cardiovascular and cerebrovascular death for 7 years of follow-up utilizing basic medical data
Updating Cardiovascular Disease Risk Prediction Equations to Account for Lipid-lowering Treatment Drop-in During Follow-up: A National Data-linkage Cohort
J Liang
Incorporating a time-dependent lipid-lowering medication effect is an effective approach for addressing treatment drop-in in CVD risk prediction equations
Traditional methods to evaluate model performance are unable to identify the impact of treatment drop-in
Digital health in hypertension management: utile or futile
Using Apps in Hypertension: A Way to Improve Blood Pressure
A Mihailidou
Apps incorporating more comprehensive functionalities will be more effective
The goal is Engagement
Partnership between patient, caregiver, and physicians to empower adherence to self-management
Assess health literacy and cultural sensitivities
Verify that it has been tested for equivalent efficacy for low and high socioeconomic status people
Guideline-directed medical therapy in heart failure: novel implementation strategies
Novel Strategies in Heart Failure Management
A Rakisheva
Rapid up-titration of HF therapies is safe and reduces HF readmissions or all-cause deaths
HFpEF patients have heterogeneous clinical profiles
Haemodynamic monitoring
Improved quality of life
Reduced heart failure hospitalisations
Hot Papers in Risk Factors and Comorbidities in Hypertension
M Camafort
Discussed 4 papers
Sacubitril/Valsartan may have advantages over valsartan in reversing ventricular remodeling
Ticagrelor Aspirin showed a greater effect in patients without hypertension than those with stroke
RIGHT: Prolongation of anticoagulant after primary PCI
Post-procedural Anticoagulation After PCI for ST-segment Elevation Myocardial Infarction (STEMI): A Multicentre, Randomised, Double-blind Trial
P Vranckx
Anticoagulation after PCI does not prevent adverse outcomes in patients with ST-segment elevation myocardial infarction (STEMI)
Routine Prolonged post-procedural anticoagulation (PPA) after PCI is safe but does not improve ischaemic outcomes at 30 days
3 anticoagulants could not prevent 30-day ischaemic events
